Search details
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Article
in English
| MEDLINE | ID: mdl-37256976
2.
HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis.
Cancer
; 130(6): 851-862, 2024 03 15.
Article
in English
| MEDLINE | ID: mdl-37933913
3.
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(6): 646-657, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37182538
4.
Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
Breast Cancer Res
; 25(1): 81, 2023 07 06.
Article
in English
| MEDLINE | ID: mdl-37415239
5.
Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases.
Int J Cancer
; 152(7): 1476-1489, 2023 04 01.
Article
in English
| MEDLINE | ID: mdl-36408915
6.
Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.
Cancer
; 129(6): 845-859, 2023 03 15.
Article
in English
| MEDLINE | ID: mdl-36655350
7.
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Cancer Immunol Immunother
; 72(8): 2729-2739, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37115210
8.
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
BMC Med
; 21(1): 300, 2023 08 09.
Article
in English
| MEDLINE | ID: mdl-37559142
9.
Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer.
J Transl Med
; 21(1): 360, 2023 06 01.
Article
in English
| MEDLINE | ID: mdl-37264417
10.
Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
BMC Cancer
; 23(1): 1175, 2023 Dec 01.
Article
in English
| MEDLINE | ID: mdl-38041048
11.
Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest.
Breast Cancer Res Treat
; 192(1): 75-87, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-35079981
12.
Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT.
Breast Cancer Res Treat
; 193(1): 65-81, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35254603
13.
Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial.
Invest New Drugs
; 40(2): 330-339, 2022 04.
Article
in English
| MEDLINE | ID: mdl-34633576
14.
A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.
Future Oncol
; 18(22): 2413-2424, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35674480
15.
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(3): 351-360, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33581774
16.
Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
Breast Cancer Res
; 23(1): 53, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-33933153
17.
Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
Int J Cancer
; 148(3): 692-701, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-32700765
18.
Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome.
Oncologist
; 26(4): e580-e587, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33191524
19.
Loss of polarity protein Par3 is mediated by transcription factor Sp1 in breast cancer.
Biochem Biophys Res Commun
; 561: 172-179, 2021 07 05.
Article
in English
| MEDLINE | ID: mdl-34023783
20.
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer.
Invest New Drugs
; 39(6): 1549-1558, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34109484